(Q50994932)

26 March 2018

title

Neurocognitive outcome in patients with hypertyrosinemia type I after long-term treatment with NTBC. (English)

1 reference

26 March 2018

author name string

Eva Thimm

1

1 reference

26 March 2018

Renate Richter-Werkle

2

1 reference

26 March 2018

Gudrun Kamp

3

1 reference

26 March 2018

Bettina Molke

4

1 reference

26 March 2018

Diran Herebian

5

1 reference

26 March 2018

Dirk Klee

6

1 reference

26 March 2018

Ertan Mayatepek

7

1 reference

26 March 2018

Ute Spiekerkoetter

8

1 reference

26 March 2018

publication date

9 November 2011

1 reference

26 March 2018

Journal of Inherited Metabolic Disease

published in

1 reference

26 March 2018

volume

35

1 reference

26 March 2018

issue

2

1 reference

26 March 2018

page(s)

263-268

1 reference

26 March 2018

https://scigraph.springernature.com/pub.10.1007/s10545-011-9394-5

exact match

0 references

cites work

Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I.

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9394-5

Outcome of tyrosinaemia type III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9394-5

Pharmacokinetics and pharmacodynamics of NTBC (2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione) and mesotrione, inhibitors of 4-hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9394-5

Liquid chromatography tandem mass spectrometry method for the quantitation of NTBC (2-(nitro-4-trifluoromethylbenzoyl)1,3-cyclohexanedione) in plasma of tyrosinemia type 1 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9394-5

Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9394-5

Nontransplant treatment of tyrosinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9394-5

Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9394-5

Tyrosinemia type II: nine cases of ocular signs and symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9394-5

NTBC treatment in tyrosinaemia type I: long-term outcome in French patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9394-5

Tyrosinemia: computed tomography, magnetic resonance imaging, diffusion magnetic resonance imaging, and proton spectroscopy findings in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9394-5

Tyrosine promotes oxidative stress in cerebral cortex of young rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9394-5

Increase of CSF tyrosine and impaired serotonin turnover in tyrosinemia type I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9394-5

Brain Magnetic Resonance Imaging in Tyrosinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9394-5

Tyrosinaemia type I: considerations of treatment strategy and experiences with risk assessment, diet and transplantation

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22069142

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Richner-Hanhart syndrome and tyrosinemia type II

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22069142

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Nitisinone: new drug. Type 1 tyrosinemia: an effective drug

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22069142

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10545-011-9394-5

1 reference

26 March 2018

PubMed ID

22069142

1 reference

26 March 2018